FDA Law Blog

MARCH 16, 2023

We are not aware of any other microbiological in vitro diagnostic test that contains the word “simple” in the regulation. symptomatic) when testing is started within 6 days of symptom onset. We note the unique use of the word “simple” to define a point-of-care device.

Marketing 40

Marketing In-Vitro Regulation Reagent 40

XTalks

JANUARY 29, 2024

Coloplast is leading by example and has launched new packaging that contains no aluminum for their soft catheter SpeediCath Flex. Coloplast is leading by example and has launched new packaging that contains no aluminum for their soft catheter SpeediCath Flex. They have created a Strive25 strategy with sustainability in mind for 2025.

Packaging 64

Packaging Packaging Production In-Vitro 64

Drug Discovery World

JULY 10, 2023

This paid-for advertorial by Taconic appeared in DDW Volume 24 – Issue 3, Summer 2023 Overcoming challenges in model generation Genetically engineered mouse models are essential tools for biomedical research. As a result, model generation is an attractive option often considered in parallel. In response, researchers often breed several founders.

Genetics 52

Genetics Gene Editing Genetic Engineering In-Vitro 52

Roots Analysis

AUGUST 15, 2023

Overview of Cell Free Systems Cell-free systems are ­in-vitro platforms which allow occurrence of biochemical reactions in the absence of living cells. Additionally, these types of cell free systems do not contain proteases and nucleases as crude cell lysates, which further helps in improving the production of many proteins.

Protein 52

Protein In-Vitro Production Reagent 52

XTalks

AUGUST 9, 2023

Xdemvy, specifically formulated as an ectoparasiticide (anti-parasitic) for Demodex blepharitis treatment, contains the active ingredient lotilaner, a member of the isoxazoline compound family. California-based Tarsus Pharmaceuticals Inc., Xdemvy is now authorized to treat Demodex blepharitis, offering a new option for affected patients.

FDA Approval 98

FDA Approval In-Vitro Trials Bacteria 98

Drug Discovery World

OCTOBER 27, 2023

Organ-on-a-chip technology allows researchers to recreate the human tumour microenvironment in vitro, using human cells and capturing much of the complexity that characterises in vivo environments,” she says. But can organ-chips entirely replace other models? Not yet, according to Ewart. While the FDA’s Modernisation Act 2.0

Research 72

Research Gene Therapy In-Vivo In-Vitro 72

Druggist

OCTOBER 21, 2020

The main products used for toenail fungus treatment are available in most pharmacies, supermarkets and perhaps with the best range of products found online. Topical products, which are applied directly to the infected area, are the main products used as toenail fungus treatment. Amorolfine 5% nail lacquer is usually applied once or twice weekly.

Production 98

Production Containment In-Vitro Sales 98

Camargo

MARCH 25, 2021

Per the FDA’s guidance on RPDD : In vitro data supporting the mechanism of action of the drug in the disease or in a related disease may suffice for rare pediatric disease designation, whereas that level of data would not generally suffice for orphan-drug designation. Criteria for Rare Pediatric Disease Designation.

Production 130

Production Drugs In-Vitro Containment 130

pharmaphorum

AUGUST 24, 2020

Container Closure Integrity Evaluation: USP Perspective. • Container Closure Integrity and Controls Strategies Ensuring Product Sterility. Monocyte Activation Test: The In-vitro Pyrogen Test Based on Human Immune Cells for Batch Release Testing of Medical Products. Container Closure Integrity Evaluation: USP Perspective. •

Contamination 52

Contamination In-Vitro Production Containment 52

Drug Discovery World

SEPTEMBER 28, 2023

In fact, the endometrial fluid contains peptides that may protect against a variety of fungi, bacteria, viruses, and other pathogens 4. Earlier this year, we explored the microbiome and its role in drug development across various therapeutic areas. The influence of these microbiomes extends to children as well.

Clinical Trials 64

Clinical Trials Clinical Trials Regulation Bacteria 64

XTalks

APRIL 13, 2021

Now, thanks to a study funded by the National Institutes of Health Intramural Research Program, scientists have discovered that ?-synuclein, synuclein, a protein involved in the formation of amyloid deposits in the brain characteristic of Parkinson’s disease and other neurodegenerative disorders, is also implicated in melanoma. Excessive levels of

Research 98

Research Protein In-Vitro Gene Therapy 98

XTalks

JANUARY 27, 2021

The company used in vitro neutralization antibody studies to evaluate the activity of Moderna’s vaccine-generated antibodies in human sera against several variants of the novel coronavirus, including the B.1.1.7 The in vitro study evaluated the ability of mRNA-1273-generated antibodies to neutralize the new SARS-CoV-2 variants.

Vaccination 52

Vaccination Vaccine In-Vitro Protein 52

FDA Law Blog

MAY 25, 2022

It is not uncommon for some in vitro diagnostic tests to suffer from poor positive predictive value, in part due to the rarity of the disease. The VALID Act would give FDA authority to regulate laboratory developed tests and fundamentally change the regulatory paradigm for all in vitro diagnostic tests. (As

Regulation 40

Regulation Genetics In-Vitro Development 40

The Pharma Data

NOVEMBER 29, 2021

First Combination of Immunotherapy With Tyrosine Kinase Inhibitor Approved in Europe for Adult Patients With Advanced or Recurrent Endometrial Carcinoma With Disease Progression on or Following Prior Treatment With a Platinum-Containing Therapy in Any Setting and Who Are Not Candidates for Curative Surgery or Radiation.

In-Vitro 52

In-Vitro Containment Development Medicine 52

The Pharma Data

OCTOBER 27, 2020

The test is planned for commercial launch as a CE-IVD ( in vitro diagnostic) certified product in the European Union in Q1 2021. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 pandemic. About XPhyto Therapeutics Corp. XPhyto Therapeutics Corp.

RNA 52

RNA Drug Delivery Production In-Vitro 52

The Pharma Data

NOVEMBER 11, 2020

ADDS IN VITRO PHARMACOLOGY AND EXPANDS PROTEIN SCIENCES. CREATES UNIQUE CO-LOCATED, FULLY-INTEGRATED, HIGH-CAPACITY R&D CENTRE. CREATES CENTRE OF EXCELLENCE FOR STRUCTURE-BASED DRUG DESIGN. INCREASES GLOBAL CAPACITY FOR HIGH-VALUE INTEGRATED DRUG DISCOVERY AND COMMERCIAL DEVELOPMENT OFFERING.

In-Vitro 40

In-Vitro Insulin Development Containment 40

XTalks

NOVEMBER 4, 2020

In the fetus, the antibody binds to fetal mast cells, a type of allergen-responsive immune cell that contains granules rich in histamine and heparin; these are released (in a process called degranulation) when the cells are stimulated by an allergen, triggering an allergic reaction. Related: Red Meat Allergy Test Gets FDA Clearance.

Allergies 98

Allergies Antibody In-Vitro Development 98

pharmaphorum

MARCH 11, 2021

The UK’s perceived failure to contain the initial spread of the virus was, we were told, in part due to a lesser focus on test and trace procedures than in some other countries, and that was down to us not having a tradition of diagnostics in this country. Over a year ago PCR testing was not a familiar term but is now known by general public.

In-Vitro 61

In-Vitro Containment Radiology Hormones 61

The Pharma Data

JANUARY 12, 2021

INCHEON, South Korea–( BUSINESS WIRE )– Celltrion Group today announced top-line results from its randomised, double-blind, and placebo controlled global Phase II/III clinical trial of CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate. days quicker compared to placebo. Patients treated with CT-P59 (40mg/kg) recovered 3.4

Clinical Trials 40

Clinical Trials Clinical Trials Trials In-Vivo 40

Camargo

FEBRUARY 16, 2021

The Camargo Blog is publishing a four-part blog series highlighting those designation programs available specifically for products with rare disease indications: Orphan Drug Designation (ODD), Rare Pediatric Disease Designation (RPDD), and Humanitarian Use Device (HUD) designation. Criteria for Orphan Drug Designation. Scientific Rationale.

Production 130

Production Drugs Marketing In-Vitro 130

The Pharma Data

JANUARY 12, 2021

Dr Graham is a medicines development expert and Infectious Diseases Epidemiologist with global Biotech and Pharma R&D experience in Phase I-IV therapeutics as well as in-vivo & in-vitro diagnostics, across many modalities. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014.

Life Science 52

Life Science Antibody In-Vivo In-Vitro 52

Drug Discovery World

OCTOBER 19, 2022

Formulations containing Carbopol polymers have been shown to provide improved retention at the target mucosal site compared with those containing alternative polymers 7. In addition, mucoadhesive excipients can benefit drug delivery when reformulating mucosal drug products or reformulating new drugs for mucosal drug products. .

Drug Delivery 52

Drug Delivery Drugs Drug Delivery Systems Development 52

The Pharma Data

JANUARY 11, 2021

Our antibody clones in their original IgG format have shown potent neutralization activity in in vitro assays and, in the case of our lead clone, in an in vivo animal model. Upon binding, the antibodies block the spike protein from interacting with ACE2 and thereby prevent virus-induced cell-killing, also known as cytopathic effect.

Antibody 52

Antibody Licensing Licensing Development 52

The Pharma Data

SEPTEMBER 1, 2020

Antigen test reliably and quickly triages people suspected of SARS-CoV-2, with results ready in 15 minutes, allowing informed treatment decisions. Antigen test accurately screens individuals with known exposure to infected SARS-CoV-2 patients, providing fast answers regarding their infection status. Food and Drug Administration (FDA).

In-Vitro 52

In-Vitro Antibody Medicine Clinical Trials 52

Drug Discovery World

AUGUST 3, 2022

These peptides typically contain up to 30 amino acids and can be cationic, amphipathic or both. Plus, in numerous in vitro experiments, the conjugate has been able to specifically enter ? Here, Bachem explores the science behind this approach. What are cell-penetrating peptides? The table below includes some of these examples.

Bioavailability 52

Bioavailability In-Vivo RNA In-Vitro 52

Advarra

SEPTEMBER 23, 2022

Whether the drug’s proposed labeling (package insert) is appropriate, and what it should contain. . The Food and Drug Administration (FDA) is the federal entity in the U.S. charged with (among other things) “ensur[ing] that safe and effective drugs are available to improve the health of the people in the United States.” .

Clinical Trials 52

Clinical Trials Clinical Trials Trials Regulation 52

The Pharma Data

DECEMBER 2, 2020

Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. SAN DIEGO, Dec. 02, 2020 (GLOBE NEWSWIRE) — Progenity, Inc. About Progenity. Progenity, Inc. Progenity, Inc. Forward Looking Statements.

In-Vitro 40

In-Vitro Sales Containment Production 40

The Pharma Data

APRIL 28, 2021

Fosmanogepix has demonstrated broad-spectrum activity in-vitro and has shown wide distribution to various tissues including the brain, lung, kidney and eye. Deal expands anti-infectives pipeline with addition of novel antifungal Phase 2 candidate, Fosmanogepix (APX001). NEW YORK–(BUSINESS WIRE)– Pfizer Inc. and Scedosporium spp).

Clinical Trials 40

Clinical Trials Clinical Trials Containment In-Vitro 40

The Pharma Data

MAY 18, 2021

5 percent of the tumour area) as determined by an FDA-approved test or are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status. The advisory committee provides the FDA with independent opinions and recommendations from outside medical experts though the recommendations are not binding.

Medicine 52

Medicine Containment In-Vitro Development 52

Pfizer

JANUARY 27, 2023

The European Commission (EC) will review the CHMP recommendation and is soon expected to make a final decision. This opinion from the CHMP confirms that the benefits of PAXLOVID in helping to reduce severe COVID-19-related outcomes, including hospitalization and death, in high risk patients continue to outweigh its potential risks.

Marketing 75

Marketing Production Drugs Licensing 75

The Pharma Data

SEPTEMBER 17, 2020

3 Knowing a given population’s seroprevalence is important in understanding how to contain the spread of the virus, as well as how to safely ease lockdown restrictions. 3 Knowing a given population’s seroprevalence is important in understanding how to contain the spread of the virus, as well as how to safely ease lockdown restrictions.

Antibody 52

Antibody Vaccination Vaccine In-Vitro 52

Pfizer

AUGUST 15, 2022

Nirmatrelvir has shown consistent in vitro antiviral activity against the following variants: Alpha, Beta, Delta, Gamma, Lambda, Mu, and Omicron BA.1 One carton contains five blister packs of PAXLOVID, as co-packaged nirmatrelvir tablets with ritonavir tablets, providing all required doses for a full five-day treatment course.

Drugs 99

Drugs Vaccination Vaccine In-Vitro 99

The Pharma Data

DECEMBER 2, 2020

SAN DIEGO, Dec. 02, 2020 (GLOBE NEWSWIRE) — Progenity, Inc. NASDAQ: PROG) today announced the pricing of its offering of $75.0 The issuance and sale of the notes are scheduled to settle on December 7, 2020, subject to customary closing conditions. million principal amount of notes. per share of common stock.

Sales 40

Sales In-Vitro Containment Development 40

The Pharma Data

OCTOBER 21, 2020

Through our collaborative research, we discovered that selective CDK9 inhibition is an attractive therapeutic strategy for transcriptionally addicted tumor types such as CRPC, and that KB-0742 reduced CRPC cell division and increased cell death in vitro, and inhibited tumor growth in a human CRPC animal model.”. SAN MATEO, Calif.,

In-Vivo 40

In-Vivo In-Vitro Bioavailability Clinical Trials 40

The Pharma Data

NOVEMBER 4, 2020

CENTOGENE’s SARS-CoV-2 test is a molecular diagnostic test performed for the in vitro qualitative detection of RNA from the SARS-CoV-2 in oropharyngeal samples from presymptomatic patients and probands according to the recommended testing by public health authority guidelines. CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov.

Genetics 40

Genetics In-Vitro Biobanking Containment 40

The Pharma Data

OCTOBER 22, 2020

Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. This press release contains forward-looking statements. DUBLIN, Ireland and CHICAGO, Oct. per ordinary share (or pre-funded warrant) and associated warrant.

In-Vitro 40

In-Vitro Clinical Trials Clinical Trials Sales 40

The Pharma Data

MARCH 16, 2021

The cobas SARS-CoV-2 Variant Set 1 Test is designed to detect key spike mutations in virus variants associated with increased human-to-human transmission. Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the cobas ® SARS-CoV-2 Variant Set 1 Test to detect and differentiate mutations found in variants that originated in the UK (B.1.1.7),

Antibody 52

Antibody Clinical Trials Clinical Trials Vaccination 52